A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...
Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...
This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...
A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
